An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a).

Jose A Caparros-MartinPatrice MaherNatalie C WardMontserrat Saladié Patricia Agudelo-RomeroStephen M StickDick C ChanGerald F WattsFergal O'Gara

Published in: Microorganisms (2024)

In statin-treated patients, the use of alirocumab to inhibit PCSK9 leads to elevated levels of fecal BAs without altering the bacterial population of the gut microbiota. The association of alirocumab with increased fecal BA concentration suggests an additional mechanism for the cholesterol-lowering effect of PCSK9 inhibition.

Keyphrases

low density lipoprotein
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
patient reported